Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors

Completed · Phase 1

Conditions studied: Brain Tumor, Brain Tumor, Recurrent, Brain Neoplasm, Brain Cancer, Glioblastoma Multiforme, Recurrent Glioblastoma Multiforme

In brief

The main purpose of this study is to evaluate the safety and performance of the AutoLITT system for the treatment of recurrent/progressive glioblastoma multiforme tumors (GBM).

Key facts

Study ID

NCT00747253

Run by

Monteris Medical

People needed

10

Starts

2008-08-01

Expected to finish

2010-04-01

Last updated by the study team

2021-08-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Previous diagnosis of GBM treated with radiotherapy with or without surgical resection and/or chemotherapy
• Clinical/radiographic suspicion of tumor recurrence/progression

You may not qualify if…

• Previous treatment of target GBM with stereotactic radiosurgery, brachytherapy, or carmustine impregnated wafers (Gliadel).

Where it is running

• University Hospitals Cleveland Medical Center — Cleveland, Ohio, United States
• Cleveland Clinic Foundation, 9500 Euclid Ave — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.